The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AmerisourceBergen; Arcus Biosciences; AskGene Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Imedex; Imugene; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Weijing Sun
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Macrogenics; Taiho Oncology
Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)
 
Caio Max Sao Pedro Rocha Lima
Research Funding - Boston Biomedical; Pharmacyclics; Rafael Pharmaceuticals
 
Satish Shah
Stock and Other Ownership Interests - Flatiron Health (I)
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Dulabh K. Monga
Consulting or Advisory Role - Aligos Therapeutics (I); AntlerA Therapeutics (I); Genentech (I); Genentech (I); Genentech (I); Revolution Medicines (I); Surrozen (I); Vicero (I)
Speakers' Bureau - BMS
Research Funding - Aligos Therapeutics (I); Alnylam (I); Fog Pharmaceuticals (I); Revolution Medicines (I); Vicero (I)
Travel, Accommodations, Expenses - Revolution Medicines (I)
 
Madappa N. Kundranda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Genomic Health; STERIS
Research Funding - Bayer (Inst); Celgene; Chronix Biomedical (Inst)
 
Amna Falak Sher
Research Funding - Seagen (Inst)
 
Philip Jordan Gold
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; insmed; ipsen; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Janssen Oncology
Consulting or Advisory Role - Olema Pharmaceuticals
Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Jacobio (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Nurix (Inst); nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); Puretech (Inst); PureTech (Inst); PureTech (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Olatunji B. Alese
Consulting or Advisory Role - AADi; Bristol-Myers Squibb; Pfizer; QED Therapeutics; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); PCI Biotech (Inst); SyncoreBio (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Aptitude Health; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; GRAIL; Macrogenics; Seagen
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Ben George
No Relationships to Disclose
 
Rutika Mehta
Honoraria - ASCO; Bristol-Myers Squibb
Consulting or Advisory Role - ASCO; Astellas Pharma; AVEO (I); BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb (I); EMD Serono (I); Guardant Health; Immunomedics (I); Lilly; NCCN/Pfizer (I); Novartis; Seagen; Seagen (I)
Speakers' Bureau - Daiichi Sankyo; Gilead Sciences (I); Natera
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Zhenzhong Xia
Employment - Ascentage Pharma Group; Transcenta
 
Caroline Germa
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - C4 Therapeutics; Immunitas
 
Nashat Y. Gabrail
Honoraria - Cardinal Health; Pharmacosmos
Consulting or Advisory Role - ClinChoice; Pharmacosmos